Clinical Trial

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-29; most recent amendment 2025-02-02.
Status change: Not Yet Recruiting → Recruiting 2025-02-02
Trial Details
NCT Number NCT06441630
Lead Sponsor Addpharma Inc.
Conditions Essential Hypertension
Enrollment 251 participants
Start Date 2024-07-31
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-02-04